Olink Holding AB (OLK)
23.99
-0.02
(-0.08%)
USD |
NASDAQ |
May 31, 16:00
24.00
+0.01
(+0.04%)
After-Hours: 20:00
Olink Enterprise Value: 2.874B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 2.874B |
| May 30, 2024 | 2.876B |
| May 29, 2024 | 2.879B |
| May 28, 2024 | 2.877B |
| May 24, 2024 | 2.871B |
| May 23, 2024 | 2.866B |
| May 22, 2024 | 2.873B |
| May 21, 2024 | 2.879B |
| May 20, 2024 | 2.866B |
| May 17, 2024 | 2.869B |
| May 16, 2024 | 2.869B |
| May 15, 2024 | 2.876B |
| May 14, 2024 | 2.840B |
| May 13, 2024 | 2.814B |
| May 10, 2024 | 2.790B |
| May 09, 2024 | 2.800B |
| May 08, 2024 | 2.809B |
| May 07, 2024 | 2.778B |
| May 06, 2024 | 2.769B |
| May 03, 2024 | 2.752B |
| May 02, 2024 | 2.753B |
| May 01, 2024 | 2.711B |
| April 30, 2024 | 2.754B |
| April 29, 2024 | 2.794B |
| April 26, 2024 | 2.731B |
| Date | Value |
|---|---|
| April 25, 2024 | 2.759B |
| April 24, 2024 | 2.680B |
| April 23, 2024 | 2.651B |
| April 22, 2024 | 2.630B |
| April 19, 2024 | 2.610B |
| April 18, 2024 | 2.660B |
| April 17, 2024 | 2.662B |
| April 16, 2024 | 2.708B |
| April 15, 2024 | 2.718B |
| April 12, 2024 | 2.728B |
| April 11, 2024 | 2.754B |
| April 10, 2024 | 2.774B |
| April 09, 2024 | 2.769B |
| April 08, 2024 | 2.780B |
| April 05, 2024 | 2.784B |
| April 04, 2024 | 2.800B |
| April 03, 2024 | 2.825B |
| April 02, 2024 | 2.812B |
| April 01, 2024 | 2.813B |
| March 31, 2024 | 2.814B |
| March 28, 2024 | 2.802B |
| March 27, 2024 | 2.814B |
| March 26, 2024 | 2.871B |
| March 25, 2024 | 2.917B |
| March 22, 2024 | 2.902B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
953.00M
Minimum
Jun 14 2022
4.510B
Maximum
Apr 27 2021
2.539B
Average
2.560B
Median
Enterprise Value Benchmarks
| Abliva AB | 10.57M |
| Karolinska Development AB | 62.17M |
| Calliditas Therapeutics AB | 1.090B |
| Oncopeptides AB | 12.46M |
| BioInvent International AB | 209.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.06M |
| Revenue (Quarterly) | 28.75M |
| Total Expenses (Quarterly) | 53.69M |
| EPS Diluted (Quarterly) | -0.13 |
| Gross Profit Margin (Quarterly) | 60.68% |
| Profit Margin (Quarterly) | -55.87% |
| Earnings Yield | -1.13% |
| Normalized Earnings Yield | -1.348 |